Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.

NCT06880757 is registered in ClinicalTrials.gov with Ankara University as lead sponsor.

NCT NCT06880757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06880757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.
Lead sponsor
Ankara University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
June 1, 2025
Completion date
June 1, 2028
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bladder (urothelial, transitional cell) cancer metastatic or unresectable